Literature DB >> 16029053

Cancer gene therapy.

Masato Yamamoto1, David T Curiel.   

Abstract

The prognosis of patients with some kinds of cancers whose patients are often found unresectable upon diagnosis is still dismal. In these fields, development of a new therapeutic modality is needed and gene therapy represents one promising strategy. So far, numerous cancer gene therapy clinical trials based on these principles have been carried out and have shown the safety of such modalities, but have fallen short of the initial expectations to cure cancers. In this review, we would like to make a problem-oriented discussion of current status of cancer gene therapy research by using mainly gastrointestinal cancers as an example. In order to overcome obstacles for full realization of cancer gene therapy, numerous researches have been conducted by many researchers. Various cancer-selective and non-selective genes, as well as lytic viruses themselves have been employed for gene therapy. In the context of gene delivery method, different kinds of viral and non-viral strategies have been utilized. In addition, surrogate assays, such as soluble markers and imaging, have been developed for safer and more informative clinical trials. Many experiments and clinical trials to date have figured out current obstacles for the realization of an effective cancer gene therapy modality. Tireless efforts to overcome such hurdles and continuous infusion of novel concepts into this field should lead to break through technologies and the cure of the patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16029053     DOI: 10.1177/153303460500400402

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  14 in total

1.  Encapsulation of adenovirus serotype 5 in anionic lecithin liposomes using a bead-based immunoprecipitation technique enhances transfection efficiency.

Authors:  Natalie Mendez; Vanessa Herrera; Lingzhi Zhang; Farah Hedjran; Ralph Feuer; Sarah L Blair; William C Trogler; Tony R Reid; Andrew C Kummel
Journal:  Biomaterials       Date:  2014-08-22       Impact factor: 12.479

Review 2.  Current issues and future directions of oncolytic adenoviruses.

Authors:  Masato Yamamoto; David T Curiel
Journal:  Mol Ther       Date:  2009-11-24       Impact factor: 11.454

Review 3.  Bacteria as vectors for gene therapy of cancer.

Authors:  Chwanrow K Baban; Michelle Cronin; Deirdre O'Hanlon; Gerald C O'Sullivan; Mark Tangney
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 4.  Role of Adenoviruses in Cancer Therapy.

Authors:  Sintayehu Tsegaye Tseha
Journal:  Front Oncol       Date:  2022-06-09       Impact factor: 5.738

5.  A probasin promoter, conditionally replicating adenovirus that expresses the sodium iodide symporter (NIS) for radiovirotherapy of prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Gene Ther       Date:  2010-04-29       Impact factor: 5.250

6.  PET imaging of heat-inducible suicide gene expression in mice bearing head and neck squamous cell carcinoma xenografts.

Authors:  J J Parry; V Sharma; R Andrews; E G Moros; D Piwnica-Worms; B E Rogers
Journal:  Cancer Gene Ther       Date:  2008-08-29       Impact factor: 5.987

Review 7.  Oncolytic virus therapy for cancer.

Authors:  Joe Goldufsky; Shanthi Sivendran; Sara Harcharik; Michael Pan; Sebastian Bernardo; Richard H Stern; Philip Friedlander; Carl E Ruby; Yvonne Saenger; Howard L Kaufman
Journal:  Oncolytic Virother       Date:  2013-09-23

8.  Viral dose, radioiodide uptake, and delayed efflux in adenovirus-mediated NIS radiovirotherapy correlates with treatment efficacy.

Authors:  M A Trujillo; M J Oneal; S J McDonough; J C Morris
Journal:  Gene Ther       Date:  2012-09-13       Impact factor: 5.250

9.  An update on canine adenovirus type 2 and its vectors.

Authors:  Thierry Bru; Sara Salinas; Eric J Kremer
Journal:  Viruses       Date:  2010-09-27       Impact factor: 5.818

10.  A steep radioiodine dose response scalable to humans in sodium-iodide symporter (NIS)-mediated radiovirotherapy for prostate cancer.

Authors:  M A Trujillo; M J Oneal; S McDonough; R Qin; J C Morris
Journal:  Cancer Gene Ther       Date:  2012-10-05       Impact factor: 5.987

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.